Analyst Expectations for ORIC Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Analysts have given ORIC Pharmaceuticals (NASDAQ:ORIC) a bullish rating in the last quarter, with an average price target of $17.0, compared to its current price of $6.0. The average price target has increased by 17.24% over the past month.
October 23, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ORIC Pharmaceuticals has received a bullish rating from analysts, with a significant upside potential based on the average price target.
The bullish rating from analysts indicates a positive outlook for ORIC Pharmaceuticals. The average price target of $17.0, compared to its current price of $6.0, suggests a significant upside potential. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100